InMed Pharmaceuticals Inc.
INM
$2.96
$0.24378.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.11M | 1.26M | 1.28M | 1.17M | 1.24M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.11M | 1.26M | 1.28M | 1.17M | 1.24M |
| Cost of Revenue | 650.80K | 771.20K | 817.00K | 883.10K | 916.10K |
| Gross Profit | 460.90K | 493.40K | 466.10K | 289.50K | 324.10K |
| SG&A Expenses | 1.55M | 1.42M | 1.21M | 1.37M | 1.36M |
| Depreciation & Amortization | 53.20K | 54.60K | 54.80K | 54.80K | 55.20K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.32M | 3.02M | 3.29M | 2.97M | 2.95M |
| Operating Income | -2.21M | -1.75M | -2.01M | -1.80M | -1.70M |
| Income Before Tax | -2.58M | -1.68M | -1.93M | -1.72M | -1.48M |
| Income Tax Expenses | -- | -- | 7.10K | -- | -- |
| Earnings from Continuing Operations | -2.58M | -1.68M | -1.94M | -1.72M | -1.48M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.58M | -1.68M | -1.94M | -1.72M | -1.48M |
| EBIT | -2.21M | -1.75M | -2.01M | -1.80M | -1.70M |
| EBITDA | -2.15M | -1.70M | -1.95M | -1.74M | -1.65M |
| EPS Basic | -3.64 | -2.71 | -4.04 | -3.58 | -3.71 |
| Normalized Basic EPS | -2.28 | -1.69 | -2.51 | -2.24 | -2.32 |
| EPS Diluted | -3.64 | -2.71 | -4.04 | -3.58 | -3.71 |
| Normalized Diluted EPS | -2.28 | -1.69 | -2.51 | -2.24 | -2.32 |
| Average Basic Shares Outstanding | 706.50K | 620.10K | 479.90K | 480.60K | 398.70K |
| Average Diluted Shares Outstanding | 706.50K | 620.10K | 479.90K | 480.60K | 398.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |